Cargando…
SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury
RNA interference mediated by small interfering RNA (siRNA) provides a powerful tool for gene regulation, and has a broad potential as a promising therapeutic strategy. However, therapeutics based on siRNA have had limited clinical success due to their undesirable pharmacokinetic properties. This stu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323819/ https://www.ncbi.nlm.nih.gov/pubmed/28251047 http://dx.doi.org/10.1002/advs.201600228 |
_version_ | 1782510100363083776 |
---|---|
author | Tang, Yaqin Zeng, Ziying He, Xiao Wang, Tingting Ning, Xinghai Feng, Xuli |
author_facet | Tang, Yaqin Zeng, Ziying He, Xiao Wang, Tingting Ning, Xinghai Feng, Xuli |
author_sort | Tang, Yaqin |
collection | PubMed |
description | RNA interference mediated by small interfering RNA (siRNA) provides a powerful tool for gene regulation, and has a broad potential as a promising therapeutic strategy. However, therapeutics based on siRNA have had limited clinical success due to their undesirable pharmacokinetic properties. This study presents pH‐sensitive nanoparticles‐based siRNA delivery systems (PNSDS), which are positive‐charge‐free nanocarriers, composed of siRNA chemically crosslinked with multi‐armed poly(ethylene glycol) carriers via acid‐labile acetal linkers. The unique siRNA crosslinked structure of PNSDS allows it to have minimal cytotoxicity, high siRNA loading efficiency, and a stimulus‐responsive property that enables the selective intracellular release of siRNA in response to pH conditions. This study demonstrates that PNSDS can deliver tumor necrosis factor alpha (TNF‐α) siRNA into macrophages and induce the efficient down regulation of the targeted gene in complete cell culture media. Moreover, PNSDS with mannose targeting moieties can selectively accumulate in mice liver, induce specific inhibition of macrophage TNF‐α expression in vivo, and consequently protect mice from inflammation‐induced liver damages. Therefore, this novel siRNA delivering platform would greatly improve the therapeutic potential of RNAi based therapies. |
format | Online Article Text |
id | pubmed-5323819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53238192017-03-01 SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury Tang, Yaqin Zeng, Ziying He, Xiao Wang, Tingting Ning, Xinghai Feng, Xuli Adv Sci (Weinh) Full Papers RNA interference mediated by small interfering RNA (siRNA) provides a powerful tool for gene regulation, and has a broad potential as a promising therapeutic strategy. However, therapeutics based on siRNA have had limited clinical success due to their undesirable pharmacokinetic properties. This study presents pH‐sensitive nanoparticles‐based siRNA delivery systems (PNSDS), which are positive‐charge‐free nanocarriers, composed of siRNA chemically crosslinked with multi‐armed poly(ethylene glycol) carriers via acid‐labile acetal linkers. The unique siRNA crosslinked structure of PNSDS allows it to have minimal cytotoxicity, high siRNA loading efficiency, and a stimulus‐responsive property that enables the selective intracellular release of siRNA in response to pH conditions. This study demonstrates that PNSDS can deliver tumor necrosis factor alpha (TNF‐α) siRNA into macrophages and induce the efficient down regulation of the targeted gene in complete cell culture media. Moreover, PNSDS with mannose targeting moieties can selectively accumulate in mice liver, induce specific inhibition of macrophage TNF‐α expression in vivo, and consequently protect mice from inflammation‐induced liver damages. Therefore, this novel siRNA delivering platform would greatly improve the therapeutic potential of RNAi based therapies. John Wiley and Sons Inc. 2016-09-02 /pmc/articles/PMC5323819/ /pubmed/28251047 http://dx.doi.org/10.1002/advs.201600228 Text en © 2016 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Papers Tang, Yaqin Zeng, Ziying He, Xiao Wang, Tingting Ning, Xinghai Feng, Xuli SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title | SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title_full | SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title_fullStr | SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title_full_unstemmed | SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title_short | SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation‐induced Liver Injury |
title_sort | sirna crosslinked nanoparticles for the treatment of inflammation‐induced liver injury |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323819/ https://www.ncbi.nlm.nih.gov/pubmed/28251047 http://dx.doi.org/10.1002/advs.201600228 |
work_keys_str_mv | AT tangyaqin sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury AT zengziying sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury AT hexiao sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury AT wangtingting sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury AT ningxinghai sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury AT fengxuli sirnacrosslinkednanoparticlesforthetreatmentofinflammationinducedliverinjury |